Logo image of FULC

FULCRUM THERAPEUTICS INC (FULC) Stock Price, Quote, News and Overview

NASDAQ:FULC - Nasdaq - US3596161097 - Common Stock - Currency: USD

6.9  +0.55 (+8.66%)

After market: 6.9 0 (0%)

FULC Quote, Performance and Key Statistics

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (5/28/2025, 8:00:00 PM)

After market: 6.9 0 (0%)

6.9

+0.55 (+8.66%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High10.13
52 Week Low2.32
Market Cap372.46M
Shares53.98M
Float52.99M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)07-29 2025-07-29/bmo
IPO07-18 2019-07-18


FULC short term performance overview.The bars show the price performance of FULC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80

FULC long term performance overview.The bars show the price performance of FULC in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100 150

The current stock price of FULC is 6.9 USD. In the past month the price increased by 89.04%. In the past year, price decreased by -12.1%.

FULCRUM THERAPEUTICS INC / FULC Daily stock chart

FULC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 52.28 681.79B
JNJ JOHNSON & JOHNSON 15.17 366.76B
NVO NOVO-NORDISK A/S-SPONS ADR 19.22 304.82B
NVS NOVARTIS AG-SPONSORED ADR 13.46 220.95B
AZN ASTRAZENECA PLC-SPONS ADR 16 218.21B
MRK MERCK & CO. INC. 9.78 191.27B
PFE PFIZER INC 7.22 131.79B
SNY SANOFI-ADR 11.79 126.53B
BMY BRISTOL-MYERS SQUIBB CO 6.4 95.59B
GSK GSK PLC-SPON ADR 8.84 79.50B
ZTS ZOETIS INC 27.48 73.64B
HLN HALEON PLC-ADR 22.96 50.66B

About FULC

Company Profile

FULC logo image Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.

Company Info

FULCRUM THERAPEUTICS INC

26 Landsdowne Street

Cambridge MASSACHUSETTS 02139 US

CEO: Robert J. Gould

Employees: 45

FULC Company Website

FULC Investor Relations

Phone: 16176518851

FULCRUM THERAPEUTICS INC / FULC FAQ

What is the stock price of FULCRUM THERAPEUTICS INC today?

The current stock price of FULC is 6.9 USD. The price increased by 8.66% in the last trading session.


What is the ticker symbol for FULCRUM THERAPEUTICS INC stock?

The exchange symbol of FULCRUM THERAPEUTICS INC is FULC and it is listed on the Nasdaq exchange.


On which exchange is FULC stock listed?

FULC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for FULCRUM THERAPEUTICS INC stock?

13 analysts have analysed FULC and the average price target is 5.44 USD. This implies a price decrease of -21.16% is expected in the next year compared to the current price of 6.9. Check the FULCRUM THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FULCRUM THERAPEUTICS INC worth?

FULCRUM THERAPEUTICS INC (FULC) has a market capitalization of 372.46M USD. This makes FULC a Small Cap stock.


How many employees does FULCRUM THERAPEUTICS INC have?

FULCRUM THERAPEUTICS INC (FULC) currently has 45 employees.


What are the support and resistance levels for FULCRUM THERAPEUTICS INC (FULC) stock?

FULCRUM THERAPEUTICS INC (FULC) has a support level at 6.84 and a resistance level at 6.91. Check the full technical report for a detailed analysis of FULC support and resistance levels.


Is FULCRUM THERAPEUTICS INC (FULC) expected to grow?

The Revenue of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -100% in the next year. Check the estimates tab for more information on the FULC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy FULCRUM THERAPEUTICS INC (FULC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FULCRUM THERAPEUTICS INC (FULC) stock pay dividends?

FULC does not pay a dividend.


When does FULCRUM THERAPEUTICS INC (FULC) report earnings?

FULCRUM THERAPEUTICS INC (FULC) will report earnings on 2025-07-29, before the market open.


What is the Price/Earnings (PE) ratio of FULCRUM THERAPEUTICS INC (FULC)?

FULCRUM THERAPEUTICS INC (FULC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.07).


What is the Short Interest ratio of FULCRUM THERAPEUTICS INC (FULC) stock?

The outstanding short interest for FULCRUM THERAPEUTICS INC (FULC) is 6.45% of its float. Check the ownership tab for more information on the FULC short interest.


FULC Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to FULC. When comparing the yearly performance of all stocks, FULC is one of the better performing stocks in the market, outperforming 94.14% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

FULC Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to FULC. FULC has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FULC Financial Highlights

Over the last trailing twelve months FULC reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 95.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -3.73%
ROE -4%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%34.88%
Sales Q2Q%N/A
EPS 1Y (TTM)95.63%
Revenue 1Y (TTM)2752.05%

FULC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 74% to FULC. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -437.82% and a revenue growth -100% for FULC


Ownership
Inst Owners96.31%
Ins Owners0.68%
Short Float %6.45%
Short Ratio6.36
Analysts
Analysts73.85
Price Target5.44 (-21.16%)
EPS Next Y-437.82%
Revenue Next Year-100%